FDA's Arthritis Advisory Committee
Will meet Jan. 23 at FDA's Parklawn building, conference rooms G, H & I to discuss ICN/Viratek's Oxsoralen (8-methoxypsoralen) in combination with Therakos' UVAR Photopherisis System for the treatment of scleroderma. The combination therapy was reviewed by the committee on Dec. 6, 1990, when it was determined that the companies needed to perform further studies ("The Pink Sheet" Dec. 10, 1990, T&G-4). The meeting is set for 9 a.m. on Jan. 23. On Jan. 24, the committee will hold a closed session beginning at 8:30 a.m. to discuss INDs 30-150 and 22-545.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth